person

Vesna T. D.

Country: Croatia
Department: Department of Oncology and nuclear medicine

Research Overview

assignment

Clinical Trials ·

CAMBRIA-2: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease

location_city

Research Sites

Opca Bolnica Zadar

Data & Insights

medical_services

Primary Speciality

Main therapeutic area

handshake

Return Partnerships

Recurring site collaborations

Sites with multiple studies

Has run more than one trial at 0 of 228 partner sites.

Specializations

Oncology

Investigator leads studies in advanced or metastatic cancer and ER+/HER2- early breast cancer.

Targeted therapy for high‑grade serous ovarian carcinoma
Adjuvant endocrine strategies in early breast cancer
Combination regimens for follicular lymphoma

Therapeutic development emphasizes efficacy and safety in solid and hematologic malignancies.

Cardiovascular & Thrombosis

Research includes atrial fibrillation management and novel anticoagulant strategies.

Non‑vitamin K oral anticoagulant alternatives
Stroke prevention in high‑risk atrial fibrillation
Evaluation of anti‑coagulation agents unsuitable for standard therapy

Focus on reducing thromboembolic events while maintaining tolerability.

Autoimmune & Inflammatory Disorders

Studies address systemic lupus erythematosus, psoriatic arthritis, systemic sclerosis, and gastrointestinal inflammation such as Crohn’s disease and ulcerative colitis.

JAK inhibitor efficacy in moderate to severe SLE
Biologic modulation in psoriatic arthritis
Targeted therapy for systemic sclerosis skin fibrosis
Therapeutic outcomes in inflammatory bowel disease

Therapeutic focus spans cytokine inhibition and disease activity reduction.

Respiratory & Pulmonary Medicine

Investigator evaluates treatments for chronic obstructive pulmonary disease and severe eosinophilic asthma.

Triple therapy augmentation in COPD
Biologic agents reducing asthma exacerbations
Inhaled molecule efficacy in airway inflammation

Aim is to improve lung function and decrease severe exacerbation rates.

Metabolic & Ophthalmic Therapeutics

Research includes severe hypertriglyceridemia and neovascular age‑related macular degeneration.

RNA‑based therapy to lower triglyceride levels
Anti‑VEGF biosimilar equivalence in macular degeneration
Lipid‑lowering strategies in high‑risk cardiovascular patients

Therapeutic goals target metabolic control and visual preservation.

Related Investigators

Researchers in similar fields or departments

Want to know more about this investigator?

We can share extended profile information and contact details.

Is something out of date?

Tell us what needs correcting and we'll update this profile.